SAR 126119Alternative Names: SAR126119
Latest Information Update: 20 May 2013
At a glance
- Originator Sanofi
- Class Anti-ischaemics
- Mechanism of Action Carboxypeptidase U inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase I Stroke
Most Recent Events
- 08 Jan 2013 Phase II development is ongoing in France
- 31 Dec 2011 Sanofi completes a phase I trial in Stroke in France during 2011
- 28 Jul 2011 Phase-I clinical trials in Stroke in France (unspecified route)